BioLife Solutions, Inc. (BULLETIN BOARD: BLFS) , a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced the addition of Colleen Delaney, MD, MSc to its Scientific Advisory Board (SAB).

Dr. Delaney is the Director of the Cord Blood Research and Transplant Program at Fred Hutchinson Cancer Research Center (FHCRC) and Seattle Cancer Care Alliance (SCCA). She is an attending physician at Seattle Children's Hospital, Assistant Member of the Clinical Research Division of FHCRC and Assistant Professor at the University of Washington School of Medicine. Dr. Delaney's research interests include hematopoietic stem cell regulation and the development of novel and clinically feasible ex vivo expansion systems for hematopoietic progenitor cells. Her goal is to improve the outcome of patients in need of a cord blood transplant. Dr. Delaney is principal investigator on five FHCRC clinical trials investigating the use of single or double unrelated donor umbilical cord blood grafts as an alternative source of stem cells for hematopoietic cell transplant, including a multi-center protocol investigating the use of single versus double unrelated donor umbilical cord blood grafts as source of stem cells for hematopoietic cells.

Dr. Delaney commented on her relationship with BioLife by stating, "I'm quite impressed with BioLife's technology. We're evaluating CryoStor™ for a potentially large scale cell bank application and so far, the increased quantity of functional cord blood derived stem cells that were frozen using CryoStor and the improvement in engraftment have been remarkable. I look forward to advising the company on a robust quality and regulatory strategy that could accelerate adoption of BioLife's products."

Chief Executive Mike Rice remarked on Dr. Delaney joining BioLife's SAB: "We're thrilled that Dr. Delaney has joined our Scientific Advisory Board. Her input on our product development and regulatory strategies will be extremely valuable as we continue to establish our biopreservation media products as new potential standards for clinical cell-based therapies sourced from cord and peripheral blood, where quality of production reagents, shelf life, process improvements, post-preservation function, and ultimately therapeutic efficacy are of great concern to manufacturers, hospitals, physicians, patients and payers."

About BioLife Solutions, Inc.:

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor™ platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's fully defined serum-free and protein-free products are manufactured under current Good Manufacturing Practices and are formulated using only USP or highest available grade components to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant yield improvement in post-preservation cell and tissue and viability and function.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the U.S. Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

   Media Relations:                Investor Relations:
   Len Hall                        Dan Matsui
   Allen & Caron Inc               Allen & Caron Inc
   (949) 474-4300                  (949) 474-4300
   len@allencaron.com              d.matsui@allencaron.com

First Call Analyst:
FCMN Contact:

SOURCE: BioLife Solutions, Inc.